Roche has reported that its cobas MTB and cobas MTB-RIF/INH tests are included in the latest World Health Organisation (WHO) policy guidelines on nucleic acid amplification tests (NAATs) for tuberculosis (TB) and drug-resistant TB detection.
The latest guidance increases the number of rapid molecular tests for national TB programmes in high-burden countries, providing multi-faceted diagnostic methods that can aid patients and communities.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The two Roche mycobacteria tests are indicated for use on the cobas 6800/8800 Systems to identify a combination of TB and drug-resistant TB infections using a single specimen obtained from the patient.
When an individual shows TB symptoms, the high-sensitive cobas MTB test is conducted. On obtaining a positive result, drug resistance is assessed with the cobas MTB-RIF/INH test.
Compared to other automated molecular platforms, the cobas 6800/8800 Systems can deliver results in less time at increased throughput and with the longest walk-away time available.
Furthermore, these systems are part of the Molecular Work Area, a completely integrated lab workflow approach that allows labs to enhance their efficacy, flexibility and scalability levels.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataRoche Diagnostics CEO Thomas Schinecker said: “Roche’s diagnostic solutions detect both TB and drug-resistant TB, enabling patients to be diagnosed earlier and treated with the appropriate regimen to stop the spread of the disease.
“Roche plays a significant role in the fight against TB through our Global Access Program, which focuses on sustainable solutions that can help diagnose infections and save lives.”
WHO guidelines are a vital step to end the TB epidemic globally by boosting patient access to high-quality tests, Roche noted.
Through its phased End TB Strategy, WHO intends to lower overall TB incidence by 90% and anticipates a 95% decline in TB deaths by 2035.
Last month, Roche received Emergency Use Authorisation from the US Food and Drug Administration for the use of its cobas SARS-CoV-2 Nucleic acid test in point of care settings.
